Under NIH exemptions, the Coriell Institute collects de-identified clinical trial samples for downstream analyses. This involves the use of strict protocols to ensure sample integrity, specimen handling, and authentication.
Downstream processes include biobanking, culturing, biomarker assays, quality control, storage, and further distribution, and may entail linkage to clinical data.
Biobanking and biomarker analysis are frequent evaluations in clinical research involving biospecimen usage and storage for future analyses.
For clinical trial support, Coriell collects deidentified patient samples, including blood, tissue biopsies, urine, and saliva, for the various laboratory analyses described on the[Epigenomics, Genomics, and Multiomics pages]. These advanced assays are then subjected to state-of-the-art bioinformatic, statistical, and computational analyses to establish the association of biomarkers (tissue samples) with specific diseases or therapeutic responses.
Coriell’s established protocols and infrastructure provide reliable, ethical, and scalable solutions for clinical trial sample collection—supporting research that leads to novel diagnostics, therapeutic development, and precision medicine breakthroughs.
